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ABSTRACT  
Major challenges in the design of oral dosage forms are their low solubility and low bioavailability. Improving the dissolution of these oral 
dosage forms are one of the most challenging tasks for the formulation scientists as most of the drug candidates are highly l ipophilic in nature. 
Telmisartan and Ezetimibe belongs to the BCS class II, having high lipophilicity, poor water solubility and poor dissolution. The objective of this 
work was to improve the dissolution rate of poorly water soluble drugs by using porous carrier drug delivery system. Templating based spray 
drying methodology was used to prepare porous mannitol. Drug (Telmisartan, Ezetimibe) loaded porous mannitol carriers then characterized 
by P-XRD, DSC, SEM, BET surface area analysis and ATR-FTIR. ATR-FTIR studies showed complete removal of templating agent from carrier. P-
XRD and DSC studies confirmed nano- confinement of drug in crystalline form. In vitro dissolution study results indicated that porous mannitol 
prepared using tartaric acid as templating agent showed significant improvement in dissolution rate than pure drugs and respective physical 
mixtures .These results suggest that, these porous carriers can be useful as drug carriers for improving the dissolution of l ipophilic drugs. 
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1. INTRODUCTION 
Major challenges in the design of oral dosage forms are their 
low bioavailability. Poor solubility is one of the main causes 
of low bioavailability [1].More than 40% of newly developed 
drugs in the pharmaceutical industry are belong to class II 
and class IV of biopharmaceutical classification system (BCS) 
[2].Improving the dissolution of these API is one of the most 
challenging tasks for the formulation scientists as most of the 
drug candidates originating from discovery are highly 
lipophilic in nature. In order to tackle problems related to 
solubility and dissolution, various approaches like 
micronization, nanosuspension, amorphous solid dispersion, 
cyclodextrin complexation, salt forms, solvates forms, 
mesoporous silica carriers have been explored till now. The 
above approaches also have some limitations like 
agglomeration after micronization, stability problems with 
nanosuspension, bulkiness of cyclodextrin complexes, 
Chances of phase transformation to crystalline state during 
processing and storage of amorphous solid dispersions [3]. 
Adsorption of drug on the silica materials to improve 
dissolution of poorly soluble drug is a novel approach [4]. 
There is increasing interest in these potential carriers due to 
some of the interesting features such as large surface area, 
pore volume, controllable structural and textural parameters 
[5]. However, these parameters may attribute to low bulk 
density, Hygroscopicity, and poor flow properties leading to 
issues in tableting process. Further, this large pore volume 
and higher surface area may not be suitable to load low dose 
drugs as it may lead to problem in content uniformity [6]. 
Therefore, the lack of down-stream process understanding of 
mesoporous silica to improve powder flow, compression and 
compaction properties while maximizing the dose, necessary 
for an oral dosage form was the driving force of this 
research.  
Recently reported methodology to prepare porous lactose 
using template assisted spray drying technique. The surface 
area and pore size distribution were less as compared to 
mesoporous carriers. The authors reported improvement in 
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dissolution of few drugs like acetaminophen, indomethacin 
and nifedipine [7-8].However, the effect of hydrophobic 
carriers on the dissolution and effect of solid state transition 
of drug (that may possible during loading procedure) is not 
taken into consideration. Hence, the present work was 
designed to overcome the lacunae present in the literature 
available. In the present work mannitol was used as carrier 
material and modified to porous mannitol by using template 
assisted spray drying technique. The effect of various temple 
ting agents, concentrations and combinations on porosity 
and dissolution rate was evaluated using telmisartan and 
ezetimibe as model drugs. The hydrophobic drugs have the 
problem of poor dissolution performance and hence poor 
bioavailability. Among all approaches used for enhancement 
of dissolution of poorly water-soluble drugs, porous drug 
delivery system has gained a lot of attention in last two 
decades. Mesoporous silica carriers are one of the approach, 
[9-10] but it has limitations of low water solubility 
Hygroscopicity, compression issues during tableting. Hence, 
in the present study mannitol was converted to porous 
carrier that can overcome the above-mentioned issues.  
Mannitol as core material and food grade acids and sugars as 
templating agents. Mannitol is water soluble, [11] 
biodegradable, biocompatible and mostly used 
pharmaceutical diluent in solid oral dosage forms. Porous 
mannitol may offer potential carrier for poorly water-soluble 
drugs despite their much lower specific surface area and 
smaller pore volume compared with those of mesoporous 
silica [12]. 
Telmisartan and ezetimibe was selected as a model drug for 
this study due to their poor aqueous solubility and high 
lipophilic nature. Thus,  making them suitable for the scope 
of this work. 
FORMULATION AND DEVELOPMENT 
Method  
Preparation of Porous Mannitol 
Required quantities of mannitol and templating agents (citric 
acid/tartaric acid) were taken and   dissolved in specific 
quantity of  Milli Q water , kept under stirring for 30 min. at 
room temperature to obtain clear solution. The clear solution 
was spray dried on spray dryer (JISL, Mumbai) with an inlet 
and outlet temperature of 140 °C and 60 °C respectively, 
aspirator rate of 1200 RPM, feed pump of specific RPM, and 
atomization pressure of 2kg/cm2.The ethanol-soluble 
templating agent was removed from the mannitol structure 
by washing the spray-dried powder with sufficient amount of 
ethanol under continuous stirring for 24 h at room 
temperature, followed by vacuum filtration to recover the 
template-free mannitol. The practical yield of spray dried 
product was calculated by using following formula: 
Practical yield (%) =(
                     
                 
)×100 
Drug loading 
Telmisartan was dissolved in mixture of dichloromethane 
and ethanol (1:1), while Ezetimibe solution was dissolved in 
acetone. The template free porous mannitol carrier was 
soaked in these solutions in RBF covered with parafilm with 
aluminum foil .The solvent was removed by using a rotary 
evaporator at 40°C temperature under vacuum. Finally, the 
product was dried in oven for few minutes to remove 
residual solvent. The percentage drug loading was calculated 
by using following formula. 
% Drug loading = (
                             
                          
)     
 Determination of drug loading 
Accurately, weighed quantity (5mg) of drug loaded porous 
mannitol was dissolved in 10mL of methanol and sonicated 
for 30 minute. The resulting solution was filtered and the 
filtrates were scanned at (232 nm for Ezetimibe,  296 nm for 
Telmisartan using a 1 cm cell). The maximum absorbance 
was determined using UV- visible Spectrophotometer (UV 
1700, Shimadzu, Japan) after appropriate dilutions in 
methanol. The above assay was done in triplicates.  
In vitro dissolution 
Preliminary dissolution studies were performed in USP type 
II dissolution tester (Electro lab-India, EDT-08Lx, Syringe 
pump (ESP: 124) and sample collector ESC: 12D) in different 
dissolution media Table: 1, Load the dissolution program as 
per parameter reported in table: 2, and allow to achieved the 
bath temperature 37ºC, to determine the discriminating 
media using pure drugs. Then, the dissolutions of pure drugs, 
physical mixture and drug loaded porous mannitol was 
performed in selected dissolution media using parameters 
given in Table:2. Here, physical mixture was prepared by 
triturating drugs with spray dried mannitol obtained after 
ethanol wash. 
 
Table: 1 Dissolution media for telmisartan and ezetimibe 
Sr.No. Dissolution media for telmisartan Dissolution media for Ezetimibe 
1 
Phosphate buffer  
( pH 7.5) (USP) 
0.45%SLS in Acetate buffer pH 4.5 (USP) 
2 
Phosphate buffer saline  
( pH 7.4) 
1% SLS in water (IP) 
3 
0.1%SLS in phosphate buffer saline  
( pH 7.4) 
0.5% SLS in Water 
4 
0.2%SLS in phosphate buffer saline 
( pH 7.4) 
0.3% SLS in Water 
5 
0.3%SLS in phosphate buffer saline  
(pH 7.4) 
0.1N Hydrochloric acid (pH 1.2) 
6 0.1N Hydrochloric acid (pH 1.2) - 
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Table 2.dissolution parameters 
Sr.No. Parameters Specification 
1 Apparatus USP II 
2 RPM 75 
3 Volume of media 900 mL 
4 Temperature 37℃±0.5℃ 
5 Sampling volume 5 mL 
6 
Weight of formulation 
 
Equivalent to 5mg telmisartan and 10mg 
Ezetimibe 
 
 
Dissolution Efficiency 
The dissolution data obtained was treated to get percentage 
dissolution efficiency. The percentage DE was calculated at 
15, 30, 60 and 120 minutes using the following formula for 
all the samples and compared. 
%DE =(
∫     
 
 
      
)×100 
Characterization methods 
Scanning electron microscopy (SEM) 
The morphology of the spray-dried mannitol before ethanol 
wash, after ethanol wash, drug loaded mannitol and physical 
mixture was examined by scanning electron microscope 
(SEM, JEOL-JSM-IT100 and SEM JOEL-6360LV, Tokyo, 
Japan). A small amount of sample was placed on an SEM stab 
using double-sided adhesive tape and coated with gold at 20 
mA for 2 minute using an auto fine coater (Ion sputter JFC 
1600). After coating, the digital images of the samples at 
different resolution ( 2000 x, 4000x , 8000x , 10000x ) were 
obtained by the SEM with secondary electron detector with 
accelerating voltage 100 kV. 
 Specific surface area analysis 
Specific surface areas of mannitol carrier before and after 
template removal were determined by using surface area 
analyzer (SMART SORB 92/93 Smart Instruments Co.(P) Ltd. 
Mumbai, India). Prior to measurements, weighed sample 
was regenerated by degassing to remove moisture and 
contamination. The regenerated sample was dipped in liquid 
nitrogen and the quantity of the adsorbed gas (70% 
Nitrogen + 30% Helium) was measured using thermal 
conductivity detector and then integrated using electronic 
circuit in terms of counts. The instrument was calibrated by 
injecting known quantity of nitrogen. The measured 
parameters were then used to calculate surface area of the 
sample by employing the adsorption theories of Brunauer, 
Emmett and Teller. 
ATR- FTIR Spectroscopy 
The chemical structure of Tartaric acid, spray dried mannitol 
before ethanol wash, after ethanol wash, pure drugs, 
physical mixtures and drug loaded porous mannitol samples 
were analysed on Spectrum Two Universal ATR sampling 
accessory (single reflection diamond) equipped with a 
LiTaO3 (Lithium tantalate) detector coupled with a 
PerkinElmer FTIR system. Each sample was placed on ATR 
sampling device and torque of 80N was applied and spectral 
scanning was taken in the wavelength region between 4000-
700 cm/s with scan speed of 1 cm/s. 
X-ray Powder diffraction (PXRD) 
PXRD pattern of pure telmisartan, porous mannitol carrier, 
optimized telmisartan loaded mannitol and solvent 
precipitated telmisartan were recorded using (MAXima X 
XRD-7000, Shimadzu, Japan , X-ray diffractometer) operated 
at a voltage of 40 kV and current of 30 mA using Cu Kα 
radiation source (1.54 Å) passing through nickel filter with 
divergence slit (10), scatter slit (10) and receiving slit (0.3 
mm) over the angular range (2θ) of 10 – 400 at a rate of 4° 
min-1 in steps of 0.020 with step time of 0.3 second. 
While, PXRD pattern of pure ezetimibe, porous mannitol 
carrier, optimized ezetimibe loaded mannitol and solvent 
precipitated ezetimibe were recorded using (PANalytical 
Empyrean Netherlands, X-ray diffractometer ) operated at a 
voltage of 45 kV ( current of 30 mAUsing Cu Kα) radiation 
source (1.54 Å), divergence slit (1/4°), fixed mask (10mm), 
BBHD (BRAGG BRENTANO HD), anti-scatter slit 1° and 
receiving slit (8 mm) over the angular range (2θ) 5°-90° in 
step size (2θ) 0.0260 with scan step time41.5650 seconds. 
Differential scanning calorimetry (DSC) 
Thermal analysis of pure drug loaded mannitol and solvent 
precipitated drugs were recorded on DSC colorimeter (DSC-
60, Shimadzu Corporation, Kyoto, japan).The accurately 
weighed sample (5 ± 2 mg) hermetically sealed in an 
aluminium pan (Sample sealer and crimper SSC- 30 
Shimadzu Corporation, Kyoto, japan).The DSC runs were 
performed over a temperature range 25ºC to 280ºC, at 
heating rate 10ºC/min under pure dry nitrogen flow of 50 
ml/min using an empty aluminium pan as reference 
 RESULTS AND DISCUSSION 
 UV- Spectral Analysis 
The absorption maximum was found to be 296 nm for 
telmisartan and 232 nm for ezetimibe. Calibration curves of 
telmisartan and ezetimibe in methanol and different 
dissolution media are presented in (figure: 1), along with 
regression equations. 
The linearity was observed in the range of 3μg/mL to 
12μg/mL for telmisartan in methanol and 4μg/mL to 
14μg/mL in 7.5 pH Phosphate buffer. In case of ezetimibe, 
the linearity was observed in the range of 3μg/mL to 
18μg/mL in both methanol and 0.3% SLS in water. 
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Figure 1: Calibration curve of Telmisartan A) methanol,  B)Phosphate buffer pH 7.5, calibration curve of ezetimibe in,  C) 
methanol,  D) 0.3%SLS in water 
 
Preparation of porous mannitol 
The porous mannitol was prepared using different 
templating agents by spray drying. The preliminary 
experiments conducted to optimized the spray drying 
parameters showed that higher feed concentrations (20% 
w/v) and higher feed rates (> 20 rpm) leads to sticking of 
samples to the walls of spraying chamber (Table:3). This 
resulted in decrease in the yield. Hence, the feed rate was 
fixed at 20 rpm and the feed concentration was optimized to 
10%w/v. Similarly, increasing the concentration of 
templating acids above 2%w/w of carrier also produced 
sticky material with low yield. This may be due to decrease 
in the glass-transition temperatures of the amorphous spray-
dried intermediate products with the use of templating acids 
with very low glass-transition temperatures. 
When the sucrose was used with citric acid (1:1) as 
templating agent the yield is increased. This increase in yield 
was associated with increase in glass transition 
temperatures of spray dried intermediate products since 
sucrose increases the glass transition temperature of 
mixture. The ascorbic acid was oxidized during spray drying 
and product converted into yellow colour so this was not 
used in further process. 
 
Table 3: Parameters for preparation of porous mannitol through spray drying 
Sr.N
o. 
Templating 
Agent 
Mannitol: 
Template 
ratio 
Water 
volume 
Feed Rate 
(RPM) 
Sticking %Yield 
1 - 10:0 50 30 More 40 
2 - 10:0 100 30 Less 47 
3 - 10:0 100 20 Less 65 
4 Citric acid 10:2 50 20 More 30 
5 Citric acid 10:2 100 20 Less 50 
6 Citric acid + 
Sucrose 
10:1:1 100 20 Less 70 
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Drug loading 
The type of solvent, volume of solvent and soaking time will 
influence the drug loading into porous mannitol. Increase in 
the drug loading was seen with increase in soaking time 
from 12 h to 24h and decrease in volume of solvent. Further, 
the solubility of drug in selected solvent also showed an 
effect on drug loading i.e. for ezetimibe more drug loading 
was obtained with acetone than ethanol. Drug loading was 
found to be decreased with increasing carrier ratio (Table: 
4)
 
Table 4: Drug loadings in porous mannitol prepared using tartaric acid as template 
Sr.no Formulation name Drug name Drug: carrier ratio % Loading 
1 F1 Telmisartan 1:1 45.73 
2 F2 Telmisartan 1:3 30.56 
3 F3 Telmisartan 1:6 15.711 
4 F4 Telmisartan 1:5 10.22 
5 F5 Ezetimibe 1:1 46.064 
6 F6 Ezetimibe 1:2 31.72 
7 F7 Ezetimibe 1:3 15.21 
8 F8 Ezetimibe 1:4 14.11 
 
In - vitro dissolution studies 
Dissolution studies were performed in different media as 
per table no.4.Pure telmisartan showed complete drug 
release within 15min from PBSpH7.4 media with 0.1%, 
0.2%, and 0.3%SLS and1.2 pH hydrochloric acid media. Also, 
Ezetimibe showed complete drug release within 15min from 
water with 1% and 0.5% SLS media and only 15% drug was 
released from 0.1N hydrochloric acid pH1.2 indicating these 
media cannot be used further to discriminate between pure 
drug and formulation. Hence, these are omitted and 
Phosphate buffer pH 7.5 for telmisartan and 0.3%SLS in 
water for ezetimibe were selected as discriminating 
dissolution media for conducting further dissolution studies. 
As templating agent plays major role in the pores formation 
on mannitol, the selection was made based on dissolution 
studies of drug loaded porous mannitol prepared with 
different templating agents at 1:4 ratio of drug to carrier. 
Dissolution profiles of telmisartan and ezetimibe loaded 
mannitol prepared from different templating agents are 
shown in figure 2A and 2B respectively. From the figure it 
was evident that, the release of both drugs was higher from 
porous mannitol prepared using tartaric acid as templating 
agent. Hence, further studies were performed by taking 
porous mannitol prepared using tartaric acid as templating 
agent.
 
 
Figure 2.Dissolution of A) telmisartan loaded porous mannitol,   B) ezetimibe loaded porous mannitol prepared using different 
templating agents, (n=3) 
 
The effect of drug to carrier ratio (1:1, 1:2, 1:4 and 1:6) on 
dissolution of telmisartan and ezetimibe was shown in 
figure3A-D and 4A-D respectively. At each ratio, the 
dissolution was compared to respective physical mixture 
and pure drug. 
In case of telmisartan, all the formulations except F1 (1:1, 
drug to carrier) dissolution was more from drug loaded 
porous carriers compared to respective physical mixture 
and pure drug (Figure 3B, C and D). In case of F1 (figure 3A) 
no significant difference was observed in drug release from 
pure drug, physical mixture and drug loaded carrier. 
Further, similarity factor values also indicated all the three 
dissolution profiles were similar in for F1. Further to 
confirm that improved dissolution is due to loading into 
carrier, telmisartan was dissolved in the same solvent used 
for drug loading in the absence of carrier and precipitated 
drug was evaluated for dissolution. No significant changes 
were observed in dissolution of precipitated drug in 
comparison to pure telmisartan indicating, no solid state 
transition took place during drug loading and the 
improvement in dissolution was purely due to loading of 
telmisartan into the porous mannitol. 
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Figure  3.  Dissolution of telmisartan formulations loaded in different ratio of drug to tartaric acid templated porous mannitol, 
respective physical mixtures and pure telmisartan in phosphate buffer pH 7.5, (n=3) 
In case of ezetimibe, dissolution was more from drug loaded 
porous carriers compared to respective physical mixture and 
pure drug except F5 and F6 (1:1 and 1:2) showed lower % 
drug release from drug loaded carriers compared to their 
respective physical mixture and pure drug (Fig.4 A-D). 
Precipitated ezetimibe also showed significantly lower 
dissolution compared to pure drug (Fig.5 B) This may be due 
to conversion of ezetimibe to different form compared to 
pure drug during loading. Formulations containing mannitol 
in higher ratios i.e.; F7 and F8 (1:4 and 1:6) showed 
significant improvement in dissolution rate. At higher carrier 
ratio the drug was incorporated into the pores which 
prevented conversion of ezetimibe to other form resulted in 
improvement of dissolution. 
 
 
Figure  4. Dissolution of ezetimibe formulations loaded in different ratio of drug to tartaric acid templated porous mannitol, 
respective physical mixtures and pure ezetimibe in 0.3 % SLS in water, (n=3) 
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Figure 5 A and 5B shows comparison of dissolution profiles 
of telmisartan and ezetimibe from different drug to carrier 
ratios indicates that, the dissolution was improved with 
increasing carrier ratio from 1:1 to 1:4 and beyond 1:4 there 
was no significant improvement in dissolution for both 
drugs. Based on these 1:4 drug to carrier was found to be 
optimized and further characterized. 
 
 
Figure  5. Dissolution of formulations prepared with different ratio of A) telmisartan to porous mannitol, B) Ezetimibe to 
porous mannitol, (n=3) 
 
Dissolution efficiency 
The increase in dissolution rate was further confirmed by 
comparing percentage dissolution efficiency of pure drug, 
physical mixtures and respective optimized formulations at 
15, 30, 60 and 120 minutes (Fig.6) Dissolution efficiency of 
Optimized formulations (F3 and F7) were significantly 
higher compared to their respective pure drug and physical 
mixtures at all-time points 
 
 
Figure  6. Percentage dissolution efficiency of A) optimized telmisartan formulation (F3), respective physical mixture and pure 
telmisartan B) optimized ezetimibe formulation (F7), respective physical mixture and pure ezetimibe. 
 
Scanning electron microscopy (SEM) 
The unprocessed mannitol is cube shaped and nonporous 
(Fig.7A). The micrographs show some morphological 
changes for the mannitol powder, before (Fig.7 B) while, 
spray dried mannitol is spherical shaped and nonporous 
(Fig.7C), after templet removal by ethanol wash (Fig.7D). 
The surfaces of the spray-dried powders appeared to be 
nonporous, while more porosity appeared to be formed on 
the surface and also inside the ethanol washed mannitol. 
This increased surface area in after ethanol washed powder 
than before ethanol washed powder was further confirmed 
by using BET analysis. 
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Figure 7: SEM images of A) Unprocessed plain mannitol, B) Before ethanol wash and Spray C) Dried mannitol, tartaric acid 
templated spray dried powder mannitol   , D) After ethanol washed. 
 
Specific surface area analysis 
The spray dried tartaric acid templated mannitol before 
ethanol washing have less BET surface area while after 
ethanol wash showed increase in surface area. Results of 
surface area analysis given in Table 5. 
 
Table 5. Results of Surface Area Analysis 
Sr.No. Description 
Surface Area (m2/gm) 
Mean SD RSD 
1 2 3 
1 Before ethanol wash 1.18 1.20 1.18 1.18 0.01 0.49 
2 After ethanol wash 3.43 3.42 3.42 3.43 0.01 0.34 
 
ATR- FTIR Spectroscopy 
The spectra of tartaric acid, spray-dried powders before and 
after ethanol wash are presented in figure 8. Absence of 
tartaric acid characteristic peaks at 1650 to 1750 cm−1(C=O 
stretching) in after ethanol wash powder (Fig 8C) compared 
to before wash carrier (Figure 8B) indicates complete 
removal of templating agent from porous mannitol. 
The ATR-FTIR spectra of telmisartan plain drug, ezetimibe 
plain drug, their respective physical mixtures with carrier, 
ethanol washed carrier and respective optimized drug 
loaded formulations are depicted in figure 8 and 9. 
Telmisartan pure drug shows characteristic peaks of -NH, -
CH, -C=O,C=C groups in IR region of 3057 cm-1, 2967 cm-1, 
1697 cm-1 and 1599 &1458 cm-1 respectively (Fig.9 P)While, 
ezetimibe plain drug shows characteristic peaks of -OH, -CH, 
C=O, - NH groups in IR region of 3240 to 3270 cm-1, 2918 cm-
1 ,1714 cm-1,1508cm-1(Fig.10P).Presence of all the 
characteristic peaks of telmisartan (Fig.9 S) and ezetimibe 
(Fig.10 S) in drug loaded mannitol indicates absence of any 
interaction between the drug and carriers. 
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Figure 8: The ATR-FTIR spectra of A) Tartaric acid, spray dried mannitol, B) Before ethanol wash, C) After ethanol wash 
 
Figure 9: The ATR-FTIR spectra of   P) Telmisartan plain drug, Q) physical mixture with after ethanol washed carrier , R) 
Ethanol washed carrier and  , S) Telmisartan loaded formulation (F3) 
 
Figure 10: The FTIR spectra of P) Ezetimibe plain drug , Q) Physical mixture with after washed carrier, R) Ethanol washed 
carriers and  S) Ezetimibe loaded formulation (F7) 
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X-ray Powder diffraction (P-XRD) 
The PXRD pattern of telmisartan formulation F3 (Fig.11R) 
have been compared with those of blank porous mannitol 
(Fig.11Q) pure telmisartan (Fig.11P), and telmisartan 
precipitates (Fig.11S) and ezetimibe 
formulations(Fig.12C),blank porous mannitol (Fig.12B), pure 
ezetimibe (Fig.12A) and ezetimibe precipitate (Fig12 D). 
These results suggested significant decrease in the peak 
intensities of the drug crystals in the PXRD patterns of the 
loaded mannitol (Fig: R and Fig: C). This may be due to 
deposition of drugs inside the nano confinements of porous 
mannitol. 
PXRD pattern of precipitated telmisartan is similar to pure 
drug indicating no polymorphic changes. However, ezetimibe 
precipitate showed presence of mixture of form A and B wich 
is reason for decrease in dissolution of precipitated 
ezetimibe as well as in lower carrier ratio formulations.
 
 
Figure 11: The PXRD spectra of   P) Telmisartan plain drug, Q) Porous mannitol, 
R) Telmisartan loaded formulation (F3)   S) Solvent precipitated telmisartan 
 
Figure 12:  The PXRD spectra of, A) Ezetimibe plain drug  B) Porous mannitol, C) ezetimibe loaded formulation(F7), 
D)Precipitated ezetimibe. 
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Differential scanning calorimetry (DSC) 
The DSC heating scans of loaded porous mannitol with 
telmisartan (Fig.13D) and ezetimibe (Fig.14D) were 
compared with those of pure crystalline drugs 
(Fig.13A,Fig.14A) and blank porous mannitol (Fig.13C and 
14C).The thermograph of pure telmisartan, and porous 
mannitol showed an endothermic peak due to the melting of 
their crystalline structures at 269.7 ֩C, and 166.63֩C, 
respectively. The DSC profiles of telmisartan loaded 
mannitol (F3) showed a shift to lower temperatures for the 
onset and the peak temperatures of the telmisartan melting 
process. This behavior can be linked with the confinement-
induced melting-point depression phenomenon, stating that 
the melting peaks of crystalline solids appear at lower 
temperature when trapped in confined spaces.The extent of 
melting-point depression depends on the size of the crystals, 
which in turn is defined by the size of the pores in which 
they are confined. A melting-point depression from 269.7 ֩C 
to 257.6 ֩C was observed (Fig.13D) for deposited telmisartan 
crystals. 
The thermographs of pure ezetimibe and porous mannitol 
carrier showed an endothermic peak due to the melting of 
their crystalline structures at 163.63 ֩C and 166.17 (Fig.14,C) 
The ezetimibe loaded particles (F7) also showed 
endothermic peak due to the melting of crystalline 
structures at 166.75 ֩C,(Fig.14D) which has onset of peak at 
163.9 ֩C which is similar to onset of peak of pure ezetimibe. 
This clears that ezetimibe and porous mannitol carrier peaks 
are merged with each other. 
 
 
Figure13.The DSC spectra of A) Telmisartan pure drug, B)Telmisartan precipitate, C) Porous mannitol ,D) Telmisartan loaded 
formulation (F3) 
 
Figure14. The DSC spectra of A) Ezetimibe pure drug, B) Ezetimibe precipitate, C) Porous mannitol, D) Ezetimibe loaded 
formulation (F7) 
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CONCLUSION 
Templating based spray drying methodology can be used to 
prepare porous mannitol. The feed rate and feed 
concentration affected the yield in spray drying process. The 
BET analysis confirmed the increase in surface area of 
mannitol carrier after washing out template using ethanol. In 
drug loading, the type of solvent, volume of solvent and 
soaking time affected the percentage drug loading. Out of all 
the templating agents and combinations, tartaric acid was 
found to be an effective templating agent at 1:4 ratio of drug 
to carrier. From the PXRD and DSC spectra it was found that 
the drugs were in crystalline from in porous mannitol and 
the reduced intensity of peaks in PXRD spectra concludes 
drug is in nano - confinements of porous mannitol. The drug 
loaded porous mannitol showed higher percentage CDR than 
pure drugs and respective physical mixtures. These results 
suggest that, mannitol porous carriers act as promissing drug 
carriers for improving the dissolution rate of lipophilic drugs 
Acknowledgement 
Authors are very thankful for guidance of Dr. Rameshwar K. 
Deshmukh. Authors are very thankful acknowledge to 
Principal and Management of SVPM’S College of Pharmacy 
Malegaon (BK) Baramati, Dist. –Pune 413115, Maharashtra, 
India , for providing the required laboratory facilities to 
carry out this work. Authors are gratefully acknowledged to 
Amoli organics, Mumbai, for providing DS. 
Ethics approval and consent to participate 
Not Applicable. 
Human and animal right 
No animals/Humans were used for studies that are base of 
this research. 
Consent for publication 
Not applicable. 
Conflict of interest 
The authors confirmed that this article content has no 
conflict of interest. 
REFERENCES 
[1] Soniwala MM, Patel PR, Mansuri NS, Parikh RK, Gohel MC. 
Various approaches in dissolution enhancement of Rofecoxib. 
Indian journal of pharmaceutical sciences. 2005; 67(1):61-70. 
[2] Gaur PK, Mishra S, Bajpai M. Formulation and evaluation of 
controlled-release of telmisartan microspheres: In vitro/in vivo 
study. Journal of food and drug analysis. 2014; 22(4):542-548. 
[3] Patel J, Dhingani A, Garala K, Raval M, Sheth N. Design and 
development of solid nanoparticulate dosage forms of 
telmisartan for bioavailability enhancement by integration of 
experimental design and principal component analysis. Powder 
technology. 2014; 258:331-43. 
[4] Kulkarni SA, Feng SS., Effects of surface modification on the 
delivery efficiency of biodegradable nanoparticles across the 
blood-brain barrier. Nanomedicine(Lond); 2011; 6:377–394. 
 [5] Chauhan NN, Patel NV, Suthar SJ, Patel JK, Patel MP. 
Micronization of BCS Class–II Drugs by Various Approaches for 
Solubility Enhancement–A Review. Research Journal of 
Pharmacy and Technology. 2012; 5(8):999-1005.  
[6] Saffari M, Ebrahimi A, Langrish T. A novel formulation for 
solubility and content uniformity enhancement of poorly water-
soluble drugs using highly-porous mannitol. European Journal of 
Pharmaceutical Sciences. 2016; 83:52-61.  
[7] Sharma DK. Solubility enhancement strategies for poorly water-
soluble drugs in solid dispersions: A review. Asian Journal of 
Pharmaceutics. 2016; (1):1-10. 
[8] Pardhi V, Chavan RB, Thipparaboina R, Thatikonda S, Naidu VG, 
Shastri NR. Preparation, characterization, and cytotoxicity 
studies of niclosamide loaded mesoporous drug delivery 
systems. International journal of pharmaceutics. 2017; 528(1-
2):202-214. 
[9] Chavan RB, Jitkar S, Pardhi V, Yadav B, Shastri NR. Inorganic 
Nanocomposites—A New Paradigm in Drug Delivery. 
InParticulate Technology for Delivery of Therapeutics 2017; 
317-357. Springer, Singapore. 
[10] Ebrahimi A, Saffari M, Langrish T. Improving the dissolution 
rate of hydrophobic drugs through encapsulation in porous 
lactose as a new biocompatible porous carrier. International 
journal of pharmaceutics. 2017 ; 521(1-2):204-213.  
[11] Tan S, Ebrahimi A, Langrish T. Template-directed flower-like 
lactose with micro-meso-macroporous structure. Materials & 
Design. 2017 ; 117:178-84. 
[12] Leung SS, Wong J, Guerra HV, Samnick K, Prud’homme RK, Chan 
HK. Porous mannitol carrier for pulmonary delivery of 
cyclosporine A nanoparticles. The AAPS journal. 2017; 
19(2):578-586. 
[13] Peng T, Zhang X, Huang Y, Zhao Z, Liao Q, Xu J, Huang Z, Zhang J, 
Wu CY, Pan X, Wu C. Nanoporous mannitol carrier prepared by 
non-organic solvent spray drying technique to enhance the 
aerosolization performance for dry powder inhalation. Scientific 
reports. 2017; 7:46517.  
[14] Littringer EM, Noisternig MF, Mescher A, Schroettner H, Walzel 
P, Griesser UJ, Urbanetz NA. The morphology and various 
densities of spray dried mannitol. Powder technology. 2013; 
246:193-200. 
[15] Bodhe, R., Deshmukh, R., Gorle, A., Shinde, R. and Bodhe, P. 
Formulation, development and evaluation of carbamazepine 
extended release tablet: dissolution apparatus USP IV. World 
journal of pharmaceutical research, 2019; 8(9):1484-1504. 
[16] Littringer EM, Mescher A, Schroettner H, Achelis L, Walzel P, 
Urbanetz NA. Spray dried mannitol carrier particles with 
tailored surface properties–The influence of carrier surface 
roughness and shape. European journal of pharmaceutics and 
biopharmaceutics. 2012; 82(1):194-204. 
[17] Saffari M, Ebrahimi A, Langrish T. A novel formulation for 
solubility and content uniformity enhancement of poorly water-
soluble drugs using highly-porous mannitol. European Journal of 
Pharmaceutical Sciences. 2016; 83:52-61. 
[18] Grigorov PI, Glasser BJ, Muzzio FJ. Formulation and 
manufacture of pharmaceuticals by fluidized‐bed impregnation 
of active pharmaceutical ingredients onto porous carriers. AIChE 
Journal. 2013; 59(12):4538-52. 
[19] Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S. 
Formulation design for poorly water-soluble drugs based on 
biopharmaceutics classification system: Basic approaches and 
practical applications. International Journal of Pharmaceutics 
2011; 420(1):1-10. 
[20] Savjani KT, Gajjar AK, Savjani JK. Drug solubility: importance 
and enhancement techniques. ISRN pharmaceutics. 2012 ; 1.:1-
10.
  
 
